PT-141: The Only FDA-Approved Peptide for Sexual Dysfunction — Approved in Premenopausal Women, Not Indicated in Men

The FDA approved it. Signed off in June 2019, under drug application NDA 210557. One of the only peptides to clear that bar for sexual dysfunction. Phase 3 randomised trials, two of them, published in a top-tier obstetrics journal. Statistically significant on the primary endpoints. That part is real.

Here’s the number they don’t lead with: 684 people started the long-term extension. 272 finished. Forty percent experienced nausea at the dose the approval is built on. The compound that holds the highest regulatory credential in peptide sexual medicine also lost more than half its long-term participants before the year was out.

And the men stacking it right now, the use case driving most of the actual demand, were not in any of those trials. The label says so in as many words: not indicated in men. The approval and the real-world use pattern are describing almost entirely different things.

What the mechanism actually is

PT-141 is bremelanotide. It’s the active breakdown product of Melanotan II, related but not identical. When people say PT-141 they mean bremelanotide, the compound that went through Phase 3 and got the FDA label. That’s the molecule.

The mechanism is genuinely different from everything else in sexual medicine. Sildenafil and tadalafil, the PDE5 inhibitors, act on the blood vessels in genital tissue. They work on the plumbing. PT-141 doesn’t touch the plumbing. It works in the brain, in the circuits that regulate desire itself, not in the body’s plumbing. Upstream of arousal, not downstream of it.

That distinction matters. A man who can’t sustain an erection and a man who has no interest in sex are experiencing different problems in different circuits. PDE5 inhibitors address one. PT-141, in theory, addresses the other. The mechanism is real. The question is what that mechanism actually predicts, and for whom.

What the trials actually proved

Two Phase 3 RECONNECT trials, studies 301 and 302. Randomised, double-blind, placebo-controlled. The women in the trials weren’t just experiencing low desire, they had a specific, formally diagnosed condition: desire that had faded after a period of normal sexual interest, affecting them broadly, not just in certain situations (Kingsberg et al., 2019, Obstet Gynecol). The trials measured two things: how much participants wanted sex, and how much the lack of it was bothering them, both tracked with standardized tools designed to catch real change from noise.

The result: statistically significant but moderate improvements versus placebo on both (Kingsberg et al., 2019). That is not a small thing. Hypoactive sexual desire disorder has a long history of failed trials. Bremelanotide at 1.75 mg subcutaneous crossed the line.

But read the completion numbers carefully. The 52-week open-label extension enrolled 684 of 856 eligible participants from the core phase. Of those 684, 272 finished the full year (Simon et al., 2019, Obstet Gynecol). The completers showed no new safety signals and sustained the gains from the core phase. But the completers are not the eligible population. They’re the subset that stayed. The long-term record belongs to the people who made it through, not to the people the compound will actually be offered to.

The side-effect profile is the context for that dropout. Nausea in 40.4% of patients. Flushing in 20.6%. Headache in 12%. Brief rises in blood pressure (Simon et al., 2019). That last one is not a warning on the label. It is a contraindication: uncontrolled high blood pressure or known heart disease rules the drug out. This is not a rounding error. At a dose used for something people do immediately before intimacy, a 40% nausea rate puts a real ceiling on who this compound works for in practice.

The efficacy is documented. The tolerability ceiling is also documented. The record isn’t a clean win. It’s a documented trade-off, in a specific population, at a specific dose, with a specific dropout curve attached.

That’s the women’s record. One population, one clinical construct, one dose. Hold it next to what’s happening in men’s clinics right now.

The male use case

Not a small one. Not a fringe one. And the evidence under it is one early study, not a Phase 3 programme. Men using this compound at scale are borrowing the logic from trials that were never about them, assuming that because the brain target is the same, the effect will be too, despite different bodies and a different underlying problem.

That extrapolation is not irrational. The mechanism is real. The same brain circuitry that drives desire in women exists in men too. But biologically plausible and demonstrated in a controlled trial are different things. The RECONNECT trials enrolled premenopausal women with a specific acquired desire-disorder construct. Men chasing a desire effect through the same injection are not getting a narrowed version of that evidence. They’re getting the mechanism argument, with nothing else underneath it.

The gap matters especially because the clinical problems aren’t equivalent. Hypoactive sexual desire in premenopausal women and male sexual dysfunction, whether that’s low desire, performance anxiety, or some interaction of the two, are not the same construct being tested in different bodies. They’re different constructs. The mechanism may be shared. One trial did test it in men who hadn’t responded to Viagra, and found a real erectile effect at 4 mg and 6 mg, safe and well tolerated (Rosen et al., 2004).

The approval is exactly as narrow as it says it is.

The side-effect ceiling in practice

The nausea number deserves its own beat because it shapes the entire real-world use case. This is an as-needed compound. You inject it before anticipated sexual activity. Four in ten users at the effective dose are spending a meaningful part of that window feeling sick (Kingsberg et al., 2019; Simon et al., 2019).

The brief rise in blood pressure is a different category of concern. It’s not nausea that passes. It’s the signal behind the contraindication (Simon et al., 2019). Uncontrolled high blood pressure or known heart disease, and the label rules the drug out. High risk without a diagnosis, and it says not recommended. The off-label male use case, which tends to run in middle-aged men where cardiovascular risk starts accumulating, is exactly the group that rule is aimed at.

Practically: bremelanotide is a subcutaneous injection, 1.75 mg, given at least 45 minutes before anticipated activity. Those are the label’s own numbers, written for the patients it was approved for. Preparing it is the same process as any other peptide in this class, mix, draw, inject. The label exists. The heart rule on it is a hard stop, not a caution. The question is whether the prescribers and patients running the off-label use case treat it that way.

Here’s the catch nobody names. The 40% nausea figure was measured at 1.75 mg, the approved dose. The only controlled test in men ran at 4 mg and 6 mg. A man borrowing this compound reads his upside off one dose and his safety off another.

What the approval actually transfers

What the RECONNECT approval establishes for a man using PT-141 off-label: mechanism plausibility. That’s it. The brain target this compound works on is real. The difference between acting on the brain versus acting on blood vessels, that distinction is real. The fact that a measured dose did something controlled and measurable in women with a clinical desire disorder is real.

What it doesn’t transfer: the approved dose, tested in men. A sense of how much is too much for his body. Any real evidence that what shifted desire in that specific group of women will do anything at all for men, a different body, different hormones, a different problem entirely.

What he does carry from the label: the side-effect profile. Nausea, flushing, brief rises in blood pressure. Those were measured in the trials that ran. There’s no reason to assume his profile is better. If anything, the heart contraindication is more, not less, relevant to the male demographic running the off-label use case.

That’s not a warning to stop. It’s the current edge of the actual record, stated plainly. The mechanism argument is real. The trial record is also real, and it is specifically not about him.

Where this goes next

What’s worth watching in the melanocortin pathway isn’t PT-141’s current off-label momentum. That momentum is running on borrowed evidence, conclusions drawn from women’s trials and stretched to fit a body they were never designed to study.

What’s worth watching is whether anyone runs the Phase 3 male study that would actually close that gap. The MC4R target is real. The upstream desire mechanism is real. If that pathway produces the same controlled signal in men that it produced in the RECONNECT trials, in a randomised study with the tolerability ceiling mapped to male physiology, that’s a different compound story than the one running right now. Not because the mechanism changes. Because the evidence would finally match the use.

The compound exists. The pathway is validated in one population. The trial that would validate the MC4R mechanism in men hasn’t been run. That’s an open question with a specific shape: does the MC4R mechanism that worked in women work the same way in men, with a tolerable side-effect profile? If someone runs that study and the answer is yes, PT-141 becomes the rare peptide with controlled evidence in both populations. That would be worth reading.